Published in AIDS Weekly, February 9th, 2009
Scientists at Washington University School of Medicine in St. Louis stepped aside and let Plasmodium falciparum, one of the deadliest strains of malaria, do a significant portion of the genetic engineering work in their new study. With that help, they could unambiguously show that the parasite relies heavily on a one-of-a-kind protein that it only makes in small quantities, two qualities that make the protein an attractive drug development target.
"The protein in question, which we're calling Pcalp, belongs to a class of cutting proteins...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2009-02-09)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.